Skip to main content

Miglustat Disease Interactions

There are 4 disease interactions with miglustat.

Moderate

Miglustat (applies to miglustat) inflammatory bowel disease

Moderate Potential Hazard, Moderate plausibility.

The safety of treatment with miglustat has not been evaluated in patients with significant gastrointestinal disease, such as inflammatory bowel disease. Continued treatment of these patients with miglustat should occur only after careful consideration of the risks and benefits of treatment.

References

  1. (2003) "Product Information. Zavesca (miglustat)." Actelion Pharmaceuticals US Inc
Moderate

Miglustat (applies to miglustat) peripheral neuropathy

Moderate Potential Hazard, Moderate plausibility.

Peripheral neuropathy has been reported in patients treated with miglustat. It is recommended to assess all patients receiving miglustat for peripheral neuropathy at the beginning and at 6 months interval of starting treatment. Caution should be instituted in patients who develop symptoms of peripheral neuropathy and cessation of therapy may be considered if appropriate.

References

  1. (2003) "Product Information. Zavesca (miglustat)." Actelion Pharmaceuticals US Inc
Moderate

Miglustat (applies to miglustat) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Miglustat is substantially excreted by the kidney. The use of miglustat in patients with severe renal impairment is not recommended (CrCl < 30 mL/min). In patients with moderate renal impairment miglustat administration should be initiated at a dose of 100 mg once a day, and in those patients with mild renal impairment, it should be started at 100 mg twice per day.

References

  1. (2003) "Product Information. Zavesca (miglustat)." Actelion Pharmaceuticals US Inc
Moderate

Miglustat (applies to miglustat) thrombocytopenia

Moderate Potential Hazard, Moderate plausibility.

Miglustat can cause a mild reduction in platelet counts. Monitoring of platelet counts is recommended, especially in patients with preexisting thrombocytopenia.

References

  1. (2003) "Product Information. Zavesca (miglustat)." Actelion Pharmaceuticals US Inc

Miglustat drug interactions

There is 1 drug interaction with miglustat.

Miglustat alcohol/food interactions

There is 1 alcohol/food interaction with miglustat.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer